Introducing Drugs
to Watch 2023

Dive into the showcase of likely blockbusters and game-changing
medications of tomorrow

Download the report
Drugs to Watch

Bimekizumab

BIMZELX®
Plaque psoriasis
Drugs to Watch

Capivasertib

AZD5363
Breast cancer
Drugs to Watch

Daprodustat

GSK1278863
Chronic kidney disease (CKD)–related anemia
Drugs to Watch

Deucravacitinib

BMS-986165
Plaque psoriasis
Drugs to Watch

Donanemab

LY-3002813
Alzheimer’s disease
Drugs to Watch

Foscarbidopa/foslevodopa

ABBV-951
Parkinson’s disease
Drugs to Watch

Lecanemab

BAN2401
Alzheimer’s disease
Drugs to Watch

Lenacapavir

GS-6207
HIV
Drugs to Watch

Mirikizumab

LY-3074828
Crohn’s disease and ulcerative colitis
Drugs to Watch

Pegcetacoplan

APL-2
Geographic atrophy (GA), Paroxysmal nocturnal hemoglobinuria (PNH)
Drugs to Watch

Ritlecitinib

PF-06651600
Alopecia areata
Drugs to Watch

Sparsentan
Focal segmental glomerulosclerosis (FSGS), IgA nephropathy
Drugs to Watch

Teclistamab

JNJ-64007957
Multiple myeloma
Drugs to Watch

Teplizumab

PRV-031
Type 1 diabetes mellitus (T1DM)
Drugs to Watch

Valoctocogene roxaparvovec

BMN-270
Hemophilia A

Key trends

Among the major factors shaping the global pharmaceutical market in 2023 are increasing demand for biologics from Mainland China, the rise of biosimilars, progress toward personalized medicines and the urgency of addressing the diseases highlighted in the United Nations Sustainable Development Goals.

Related content

Podcast 

Extending the human lifespan
Article 

Drugs to Watch: What are the drivers and barriers for future blockbusters?
Podcast 

Looking ahead to 2023: CEOs contemplate the new normal

From innovation to bottom line

Access global intelligence, advanced analytics and global experts from Clarivate.

Contact our team